Clinical Trials

335 enrolled

Phase 2 Not yet recruiting

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05554419 2026-03-18

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

184 enrolled

Leukemia, Myeloid, Acute

NCT05564390 2026-03-18

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Phase 1 Recruiting

24 enrolled

Leukemia, Myeloid, Acute

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Phase 2 Completed

75 enrolled 14 charts

Leukemia, Myeloid, Acute

NCT04231851 2026-03-06

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

30 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT02286726 2026-03-04

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

Phase 2 Completed

56 enrolled 11 charts

Leukemia, Myeloid, Acute

NCT04293562 2026-02-24

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Phase 3 Recruiting

1,186 enrolled

Leukemia, Myeloid, Acute

NCT03629171 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute

NCT03672539 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03896269 2026-02-20

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1 Recruiting

38 enrolled

Leukemia, Myelomonocytic, Chronic

NCT05656248 2026-02-04

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

25 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

50 enrolled 12 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04128748 2025-12-17

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

52 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04493164 2025-11-21

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

30 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03878199 2025-09-15

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Phase 1/2 Completed

12 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04990102 2025-07-29

Phase IB/II of CPX-351 for Relapse Prevention in AML

Phase 1/2 Recruiting

24 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03897127 2025-07-17

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

882 enrolled

Leukemia, Myeloid, Acute

NCT04668885 2025-07-15

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

13 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT04195945 2025-07-10

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

60 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT07008638 2025-07-09

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Recruiting

32 enrolled

Leukemia, Myeloid, Acute

NCT03844997 2025-05-31

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Phase 1/2 Completed

35 enrolled 15 charts